Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock Has Average Target Price of $11.00

Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.00.

Several brokerages have recently commented on CLRB. Weiss Ratings restated a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Thursday, October 15th. Wall Street Zen lowered shares of Cellectar Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

View Our Latest Analysis on Cellectar Biosciences

Cellectar Biosciences Stock Performance

Shares of CLRB opened at $1.14 on Monday. The firm has a market cap of $11.45 million, a PE ratio of -0.39 and a beta of 0.65. The firm’s 50 day moving average price is $1.63 and its 200 day moving average price is $2.52. Cellectar Biosciences has a twelve month low of $1.11 and a twelve month high of $4.70.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.10. On average, sell-side analysts anticipate that Cellectar Biosciences will post -2.31 earnings per share for the current fiscal year.

About Cellectar Biosciences

(Get Free Report)

Cellectar Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for cancer. Its proprietary phospholipid ether (PLE) platform is designed to help compounds selectively accumulate in cancer cells. The company’s lead investigational program is iopofosine I 131, also known as CLR 131, a radiotherapeutic that uses iodine-131 to deliver radiation to cancer cells. Cellectar has studied the candidate in multiple myeloma and other blood cancers. Cellectar’s research and development activities also include other programs based on its PLE platform.

See Also

Analyst Recommendations for Cellectar Biosciences (NASDAQ:CLRB)

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.